Key result
Fixed-dose irbesartan/hydrochlorothiazide is more effective than valsartan/HCTZ and comparable to losartan/HCTZ in patients failing monotherapy, and achieves rapid BP reductions as initial therapy.
Why the study?
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control in patients with hypertension compared to monotherapy or other combinations?
Population
Patients with hypertension whose blood pressure is not adequately controlled on monotherapy, and patients…
Comparison
Fixed-dose irbesartan/hydrochlorothiazide (HCTZ) vs Antihypertensive monotherapy, fixed-dose…
Design
Review
Authors
Loading...
May support irbesartan/HCTZ selection for uncontrolled hypertension; leaves open need for prospective head-to-head RCTs.
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control in patients with hypertension compared to monotherapy or other combinations?
Fixed-dose irbesartan/hydrochlorothiazide is an effective combination therapy for achieving blood pressure targets in patients with hypertension, both as initial therapy for moderate/severe cases and for those failing monotherapy.
Peter Bramlage (2009) conducted a review in Hypertension. Fixed-dose irbesartan/hydrochlorothiazide vs. Fixed-dose valsartan/HCTZ (80/12.5 mg), fixed-dose losartan/HCTZ (50/12.5 mg), or irbesartan monotherapy was evaluated on Blood pressure reduction and target achievement. Fixed-dose irbesartan/hydrochlorothiazide is more effective than valsartan/HCTZ and comparable to losartan/HCTZ in patients failing monotherapy, and achieves rapid BP reductions as initial therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: